Related Experiment Video
Updated: Aug 14, 2026
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Molecular mechanism of action of newer thrombolytic agents
1Center for Thrombosis and Vascular Research, University of Leuven, Belgium.
Abstract:
Recombinant tissue-type plasminogen activator (rt-PA) and single chain urokinase-type plasminogen activator (scu-PA) are thrombolytic agents, characterized by a high but not absolute degree of fibrin specificity that is mediated through different molecular mechanisms. Both activators are still under clinical investigation but it has become apparent that their therapeutic dose in humans is high and associated with a variable degree of systemic activation of the fibrinolytic system and fibrinogen breakdown. Therefore, the quest for further improvement of agents and therapeutic schemes continues. Research is being pursued in this area along the following lines: 1) tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator in molar ratios of 4:1 to 1:4 do not act synergistically on thrombolysis in a plasma environment in vitro, but display significant synergism in animal models of thrombosis. In pilot studies in patients with coronary artery occlusion, rt-PA and scu-PA are markedly synergistic and efficient thrombolysis can be obtained with a fivefold lower combined dose than that of the separate agents. The combined dose does not seem to induce systemic fibrinogen breakdown. 2) Deletion mutants of rt-PA can be constructed with a significantly prolonged half-life in vivo, and a better thrombolytic potential after bolus intravenous injection. 3) Cleavage site-specific mutants of scu-PA that abolish the conversion to urokinase may have a higher fibrin specificity. The mutants constructed thus far, however, seem to have a lower specific thrombolytic activity.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Researchers are exploring new ways to improve thrombolytic agents like recombinant tissue-type plasminogen activator (rt-PA) and single chain urokinase-type plasminogen activator (scu-PA) for better clot dissolution. Combining these agents shows promise for enhanced efficacy and reduced side effects.
Area of Science:
- Biochemistry
- Pharmacology
- Cardiovascular Research
Background:
- Recombinant tissue-type plasminogen activator (rt-PA) and single chain urokinase-type plasminogen activator (scu-PA) are fibrin-specific thrombolytic agents.
- Current clinical investigations reveal high therapeutic doses, leading to systemic fibrinolysis and fibrinogen breakdown.
- Ongoing research aims to enhance thrombolytic agents and therapeutic strategies.
Purpose of the Study:
- To investigate synergistic effects of rt-PA and scu-PA in thrombolysis.
- To explore modified rt-PA and scu-PA variants for improved therapeutic potential.
- To assess the safety and efficacy of combined thrombolytic therapy.
Main Methods:
- In vitro thrombolysis assays with varying rt-PA and scu-PA ratios.
- In vivo thrombosis animal models.
- Pilot studies in patients with coronary artery occlusion.
- Construction and evaluation of rt-PA deletion mutants and scu-PA cleavage site-specific mutants.
Main Results:
- Synergism between rt-PA and scu-PA observed in animal models and human pilot studies, enabling lower combined doses.
- Combined therapy demonstrated efficient thrombolysis with reduced systemic fibrinogen breakdown.
- Engineered rt-PA mutants showed prolonged half-life and improved thrombolytic potential.
- scu-PA mutants exhibited altered fibrin specificity but reduced thrombolytic activity.
Conclusions:
- Combined administration of rt-PA and scu-PA offers a synergistic and potentially safer thrombolytic approach.
- Development of modified plasminogen activators holds promise for enhanced thrombolytic therapy.
- Further research into optimized dosing and novel agent design is warranted for effective clot dissolution.
Related Concept Videos
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Clot Retraction and Fibrinolysis
01:29Venous Thrombosis III: Interprofessional Care